• 한국임상약학회지
• /
• 제23권2호
• /
• pp.142-150
• /
• 2013

Background: Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease, affecting most of those who are receiving dialysis. Cinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower PTH levels in dialysis patients. Objective: This study aimed to assess efficacy, safety and appropriateness of use of cinacalcet in dialysis patients. Method: This retrospective study was performed on total 24 cases with identified intact parathyroid hormone (iPTH), serum calcium and phosphorus levels before and 4 weeks after cinacalcet initiation at a teaching hospital from July 1st, 2011 to October 31st, 2012. Results: Cinacalcet decreased iPTH by 19% from baseline after 4weeks treatment and it was statistically significant (p<0.001). Cinacalcet also significantly decreased iPTH levels regardless of dialysis modality (hemodialysis group versus peritoneal dialysis group) and severity of SHPT (iPTH 300-800 pg/ml group versus iPTH >800 pg/ml group). Serum calcium, phosphorus and Ca x P levels were decreased without statistical significance. Gastrointestinal events, headache and hypocalcemia were the most common side effects. Monitoring for iPTH and serum calcium was not performed appropriately. 43.7% patients initiated cinacalcet therapy at serum calcium level< 9.0 mg/dl. Conclusion: In conclusion, cinacalcet lowers parathyroid hormone levels with no serious side effects. However, it is required to avoid cinacalcet treatment in patients with low serum calcium levels and monitor iPTH and serum calcium levels during cinacalcet administration.

• 한국임상수의학회지
• /
• 제25권4호
• /
• pp.236-240
• /
• 2008

부갑상샘 호르몬 (PTH)은 칼슘과 무기인의 수송을 조절한다. 속발성 부갑상샘 기능항진증은 대개 만성신부전에서 발생하고, 이는 개와 고양이에 있어서 CRF의 일반적인 합병증이다. 신부전을 갖는 21마리의 개가 본 연구에 사용되었다. 공시동물로부터 채혈한 혈액 중 칼슘 (Ca),무기인 (iP), PTH의 농도를 측정하여 칼슘과 무기인의 비율에 따라 두 군으로 분류하였다 (Ca / iP $\leq$ I; 그룹 1, Ca/ip $\geq$ 1.5; 그룹 II). 성과 연령 사이에 부갑상샘 호르몬 수준은 유의성 있는 차이가 없었다. 두 군 사이에 부갑상샘 호르몬 수준과 Ca/P의 비율에는 유의성 (p<0.0001)있는 차이가 나타났다. 결론적으로, 칼슘과 무기인의 비율은 신부전을 갖는 개에서 부갑상샘 호르몬 수준을 예측하기 위한 지표로 이용될 수 있을 것으로 생각된다.

• Journal of Photoscience
• /
• 제8권3_4호
• /
• pp.87-92
• /
• 2001

Intramolecular excimer formation of 1,3-di(1-pyrenyl)propane (Py-3-Py) and fluorescence polarization of 1,6-diphenyl-1,3,5-hexatriene (DPH) were used to investigate the effects of parathyroid hormone (PTH) on the bulk bilayer fluidity of the plasma membrane vesicles isolated from cultured osteoblasts (OB-PMV). In a dose-dependent manner, rat PTH-(1-34) [rPTH-(1-34)] increased the excimer to monomer fluorescence intensity ratio (I'/I) of Py-3-Py and decreased the anisotropy (r) of DPH in OB-PMV. This indicates that PTH increased both the lateral and rotational diffusion of the probes in OB-PMY. Selective quenching of DPH fluorescence by trinitrophenyl groups was utilized to examine the transbilayer fluidity asymmetry of OB-PMV. The anisotropy, limiting anisotropy, and order parameter of DPH in the inner monolayer were 0.024, 0.032, and 0.062 greater than calculated for the outer monolayer of OB-PMY. Selective quenching of DPH fluorescence by trinitrophenyl groups was also utilized to examine the transbilayer effects of PTH on the fluidity of OB-PMV. rPTH-(1-34) had a greater fluidizing effect on the outer monolayer as compared to the inner monolayer of OB-PMV. Thus, it has been proven that PTH exhibits a selective rather than nonselective fluidizing effect within transbilayer domains of OB-PMV.

• Preventive Nutrition and Food Science
• /
• 제1권1호
• /
• pp.80-86
• /
• 1996

Parathyroid hormone(PTH) is known to stimulate bone resorption and to inhibit bone collagen synthesis. In contrast, as the evidence of stimulation of bone formation by PTH has recently been observed, the study on the role of PTH involved in osteoporosis draws remarkable attention. This study has dealt with the role of alkaline phoshatase(AP), a marker enzyme for bone formation and osteoblast action, Animals(BALS/cmice) were divided into three dietary groups(high and medium Ca and Ca-free) and hormones including PTH, calcitonin(CT), cholecalciferol(citamin D) were i.p. injected. AP in the serum and liver was measured using Sigma 221 alkaline buffer solutions containing 9mM of p-nitrophenyl phoshate. Enzume was reacted at 37$^{\circ}C$ for 10 minutes and the reaction was stopped by 1.8ml of 0.1N NaOH and measured at 410nm. We found that serum and liver AP activity was increased by low dietary Ac. Compared to the control, and serum Ap activity was enhanced by PTH and vitamin D regardless of the dietary Ca. On the other hand, liver AP activity was inhibited by OTH and vitamin D at all levels of dietary Ca. CT inhibited the action of PTH and vitamin D in the serum. But, the inhibition of PTH and vitamin D action by CT was not observed in the liver, unlike in the case of serum.

• Journal of Nutrition and Health
• /
• 제29권9호
• /
• pp.1013-1020
• /
• 1996

The purpose of this study was to investigate nutrient intake and bone status in rural postmenopausal women in Korea. Ten postmenopausal women in An-Sung area participated in this study and they were divided into two groups ; women in group I had been postmenopausal for 4 years or less and those in group II had been postmenopausal for 5 years or more before the present study began. Their environmental factors and dietary intakes were surveyed through the personal interviews. Serum levels of calcium, phosphorus, parathyroid hormone(PTH), estradiol and urinary Ca, P, creatinine, hydroxyproline levels were measured from December 4 to December 27 in 1993. The reults of this study are summarized as follows : Average ages of group I and II were 54.8 and 57.2 years. Average menopausal ages of group I and II were 50.8 and 47.3 years. The nutrient intakes of subjects were higher than recommended dietary allowances(RDA) except calorie, protein, calcium, and vitamin A. The nutrient status did not show any significant difference between group I and II. Serum levels of Ca, P, PTH, estradiol and urinary P, creatinine excretion did not show any significant difference between group I and II, and all levels were in normal range. Urinary Ca excretion(p<0.05) and hydroxyproline excretion(p<0.01) were significantly lower in group I than in group II. Urinary Ca/creatinine(Ca/cr) and hydroxyproline/creatinine(Hpr/cr) rations were significantly higher in group II than in group I(p<0.01. And Hpr/cr levels of group I were in normal range, but most of subjects in group II were higher than 0.017 indicating sign of osteoporosis. Correlations between parameters showed that serum PTH adn urinary Ca, Ca/cr levels were positive related (p<0.01), and the years of the after menopausal year and urinary Hpr/cr was also positive related(p<0.05). The present results suggests that it is difficult to protect postmenopausal women's bone destruction having Korean usual diets. Therefore, to prevent osteoporosis with aging, minimizing the hormonal changes in postmenopausal women is needed as well as Ca supplementation and proper exercise before menopause begins.

• Tuberculosis and Respiratory Diseases
• /
• 제47권4호
• /
• pp.525-532
• /
• 1999

악성질환에서 체액성 고칼슘혈증은 주로 부갑상선호르몬관련단백질(parathyroid hormone related hormone ; PTHrP)이 매개물질로 작용하여 발생한다. 이러한 PTHrP포 인한 고칼슘혈중이 발생한 경우에는 원발성부갑상선기능항진증을 동반한 경우를 제외하고는 모든 환자에서 부갑상선호르몬(PTH) 농도는 저하되며 PTHrP는 증가하는 것으로 알려져있다. 특히 부갑상선이외의 종양에서 이소성 부갑상선호르몬을 생성한다거나 PTH와 PTHrP를 동시에 산생하는 경우는 매우 드물다. 저자들은 고칼슘혈증을 동반한 편평상피세포 폐암환자에서 혈청 부갑상선호르몬(PTH)과 부갑상선호르몬관련단백질(PTHrP)이 동시에 증가된 1례를 경험하여 이에 보고한다. 61세 남자 환자로서 혈청 칼슘은 7.5 mEq/L로 증가되어 있었으며, iPTH와 PTHrP(C 말단 부위 : 109-138)는 각각 150 pg/mL, 99.1 pmol/L로 모두 상승되어 있었다. 골전이나 부갑상선 기능 장애의 동반여부를 알기 위해서 시행한 골스캔이나 경부초음파, 전산화단층촬영, Tc-99m MIBI 스캔 검사에서 모두 정상소견을 보였다. 결론적으로, 본 증례는 고칼슘혈증을 보인 편평상피상피세포 폐암환자에서 PTH와 PTHrP가 동시에 증가된 경우이다. 이러한 매개물이 동시에 증가한 원인으로 PTH와 PTHrP을 분비하는 타병변이 있을 수 있지만, PTH와 PTHrP를 동시에 분비할 수 있는 주된 기관인 부갑상선에 대한 상기 검사상 특이한 이상소견이 없었던점으로 미루어 보아 편평상피세포 폐암조직으로부터 이소성 PTH와 PTHrP가 동시에 분비되었을 가능성도 있다.

• 한국식품영양과학회지
• /
• 제28권3호
• /
• pp.677-684
• /
• 1999

This study has dealt the effect of Ca regulating hormones and dietary Ca levels on Ca metabolism. Animals(BALB/c mice) were divided into three dietary groups(high and medium Ca and Ca free) and hormones including parathyroid hormone(PTH), calcitonin(CT), cholecalciferol(Vit D) were i.p. injected. After feeding experimental diets for five weeks, mice were anaethetized and sacrificed by heart puncture. We found that femur growth of mouse was slightly increased by high dietary Ca without showing statistical significance comparing to low dietary Ca group. The combination of PTH and CT showed the same effect when dietary Ca was high. At the same time, total mineral retention in bone was most affected by dietary Ca. In general, high Ca diet elevated Ca level in the serum. When dietary Ca was low, PTH stimulated Ca release from the bone into the serum, which was shown to be inhibited by CT treatment. Comparing to the control, PTH, Vit D and CT together tended to inhibit serum Ca level at high and medium dietary Ca. PTH and Vit D inhibited Ca reserve in the liver at all dietary levels of Ca. Both PTH and Vit D stimulated bone Ca retention when dietary Ca was low, but this effect was reversed when dietary Ca was high. When PTH, Vit D and CT were administered together, bone Ca level was greatly enhanced at low dietary Ca than at high dietary Ca, which suggests that these hormonal cooperation is needed for proper bone density maintenance especially when dietary minerals are not sufficient.

• Journal of Korean Neurosurgical Society
• /
• 제43권5호
• /
• pp.227-231
• /
• 2008

Objective : Earlier reports have revealed that the incidence of posttraumatic hydrocephalus (PTH) is higher among patients who underwent decompressive craniectomy (DC). The aim of this study was to determine the influencing factors for the development of PTH after DC. Methods : A total of 693 head trauma patients admitted in our hospital between March 2004 and May 2007 were reviewed. Among thee, we analyzed 55 patients with severe traumatic brain injury who underwent DC. We excluded patients who had confounding variables. The 33 patients were finally enrolled in the study and data were collected retrospectively for these patients. The patients were divided into two groups: non-hydrocephalus group (Group I) and hydrocephalus group (Group II). Related factors assessed were individual Glasgow Coma Score (GCS), age, sex, radiological findings, type of operation, re-operation and outcome. Results : Of the 693 patients with head trauma, 28 (4.0%) developed PTH. Fifty-five patients underwent DC and 13 (23.6%) developed PTH. Eleven of the 33 study patients (30.3%) who had no confounding factors were diagnosed with PTH. Significant differences in the type of craniectomy and re-operation were found between Group I and II. Conclusion : It is suggested that the size of DC and repeated operation may promote posttraumatic hydrocephalus in severe head trauma patients who underwent DC.

• Journal of Nutrition and Health
• /
• 제29권7호
• /
• pp.758-771
• /
• 1996

This study attempted to define reference data for the distribution of vitamin d status and to explore the relationship between vitamin D status and related biochemical indices in Korean women. The vitamin D status of 179 Korean women aged from 20 to 75 years was analyzed by using HPLC(High Pressure Liquid Chromatography). Related biochemical indices such as iPTH, alkaline phosphatase, creatinine, albumin, Ca, Mg and P were also measured. The mean serum level of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were s25.8ng/ml and 89.8pg/ml, respectively. Low 25-hydroxyvitamin D (<25nmol/L) was found in 29 subjects(16.5%). There was a significantly progressive decrease in serum 25-hydroxyvitamin D with increasing age(p<0.05). After in their, there was a dramatical reduction in 25-hydroxyvitamin D(p<0.05). It was also significant in post-menopasusal women compared with pre-menopausal women(p<0.000). Serum alkaline phosphatase levels increased significantly with age(p<0.001). Whereas serum calcium and phosphorus levels remained constant with age. Serum 250-hydroxyvitamin D was invesely related to iPTH (p<0.05) and alkaline phophatase (p<0.001).

• Korean Journal of Radiology
• /
• 제25권3호
• /
• pp.289-300
• /
• 2024

Objective: To prospectively evaluate the outcomes of ultrasound (US)-guided radiofrequency ablation (RFA) in tertiary hyperparathyroidism (THPT). Materials and Methods: Patients with THPT underwent RFA between September 2017 and January 2022. Laboratory parameters, including serum intact parathyroid hormone (iPTH) levels, were monitored for 48 months after RFA and compared with the levels at baseline. Complications related to RFA and changes in hyperparathyroidism-related clinical symptoms were recorded before and after RFA. Results: A total of 42 patients with THPT were recruited for this study. Ultimately, 36 patients with renal failure and 2 patients who underwent successful renal transplantation (male:female, 17:21; median age, 54.5 years) were enrolled. The follow-up time was 21.5 ± 19.0 months in the 36 patients with renal failure. In these 36 patients, iPTH levels were significantly decreased to 261.1 pg/mL at 48 months compared with the baseline value of 1284.9 pg/mL (P = 0.012). Persistent hyperparathyroidism, defined as iPTH levels maintained at > 585.0 pg/mL for 6 months after treatment, occurred in 4.0% of patients (1/25). Recurrent hyperparathyroidism, defined as iPTH levels > 585.0 pg/mL after 6 months, were 4.0% (1/25) and 0.0% (0/9) at 6 months and 4 years after treatment, respectively. In two patients with THPT after successful renal transplantation, iPTH decreased from the baseline value of 242.5 and 115.9 pg/mL to 171.0 and 62.0 pg/mL at 6 months after treatment. All complications resolved within 6 months of ablation without medical intervention, except in 10.5% (4/38) patients with permanent hypocalcemia. The overall symptom recovery rate was 58.8% (10/17). The severity scores for bone pain, arthralgia, and itchy skin associated with hyperparathyroidism improved after treatment (P < 0.05). Conclusion: US-guided RFA is an effective and safe alternative to surgery in the treatment of patients with TPTH and improves hyperparathyroidism-related clinical symptoms.